



March 23, 2026

NYSDOH Recommends Immunizing Infants with RSV Monoclonal Antibodies through April 2026, Given Ongoing RSV Disease Activity

Dear Colleague,

Respiratory syncytial virus (RSV) activity started later than usual in many U.S. regions this season, including in [New York State](#). [New York State Department of Health \(NYSDOH\)](#) data shows that RSV activity remains elevated. These findings indicate RSV infections in young children are likely to continue into April 2026.

Implications for RSV Prevention Product Use

The RSV immunization season for infants typically runs from October 1st through the end of March, with immunizations (nirsevimab or clesrovimab) administered during, or just before, this period to protect all babies under 8 months and those 9 to 18 months with conditions that make them at high risk for severe RSV disease. However, for this current 2025-2026 RSV season, NYSDOH recommends continuing administration of RSV monoclonal antibody products (RSV-mAb) for infants (nirsevimab and clesrovimab) **until April 30, 2026**, due to this statewide RSV activity. NYSDOH will continue to [monitor](#) RSV activity in New York State to guide if any additional recommendations are needed for the remainder of the 2025-2026 season.

NYSDOH recommends that health care providers continue administering RSV-mAb through April 30th, for infants and young children who are eligible and have not yet received a dose during the current RSV season. As a reminder:

Infants less than 8 months of age born during or entering their first RSV season should receive nirsevimab or clesrovimab if:

- Pregnant parent did not receive RSVpreF (Abrysvo) vaccine during this pregnancy,
- Pregnant parent's RSV vaccination status is unknown, or
- Infant was born <14 days after the pregnant parent's RSVpreF (Abrysvo) vaccination

Children aged 8 months through 19 months who are at [increased risk](#) of severe RSV disease entering their second season remain eligible during this same period.

- Only nirsevimab is recommended as a first or second dose.

Infants who receive RSV-mAb during the 2025-26 season should not receive an additional dose in the 2026-27 season unless they meet criteria for increased risk in their second RSV season.

Maternal RSV vaccination for the 2025-26 respiratory virus season concluded on Jan. 31, and continued use is not recommended.

Coverage Details

New York State Vaccines for Children Program (NYS VFC) will continue to have RSV-mAb doses available for enrolled providers to order in April.

Health insurers that issue comprehensive health insurance policies must cover RSV-mAb products through April. Providers should verify coverage with individual plans if questions arise.

Please email immunize@health.ny.gov if you have any questions.

Thank you for your work in caring for the youngest New Yorkers.

Sincerely,

Debra Blog, MD, MPH
Medical Director, Division of Vaccine Excellence
New York State Department of Health

Resources

- American Academy of Pediatrics (AAP): [RSV Immunization Administration](#)
- NYSDOH: [New York State Respiratory Surveillance and Reports](#)